7149-42-0

Usage

Uses

Used in Pharmaceutical Industry:
(1-METHYL-4-PIPERIDINYL)METHANAMINE is used as a reagent for the synthesis of novel indole-carboxamides, which are inhibitors of neurotropic alphavirus. These indole-carboxamides have potential applications in the treatment of viral infections, particularly those caused by neurotropic alphaviruses, due to their ability to inhibit viral replication and reduce the severity of the disease.
Additionally, (1-METHYL-4-PIPERIDINYL)METHANAMINE may also be utilized in other industries for different purposes, such as in the synthesis of other bioactive compounds or as an intermediate in the production of specialty chemicals. However, the primary application of (1-METHYL-4-PIPERIDINYL)METHANAMINE lies in its role as a reagent in the pharmaceutical industry for the development of antiviral agents.

InChI:InChI=1/C7H16N2/c1-9-4-2-7(6-8)3-5-9/h7H,2-6,8H2,1H3

Upstream product

• 20691-92-3 1-methylpiperidine-4-carbonitrile 
• 39546-32-2 4-carboxamidopiperidine 
• 62718-28-9 1-methylpiperidine-4-carboxamide 

Downstream Products

• 600725-10-8 N-(1-methyl-piperidin-4-ylmethyl)-benzene-1,2-diamine 
• 1089672-70-7 C₂₇H₃₄N₆O₂ 
• 1401618-75-4 1-(1-(4-chlorobenzyl)-1H-indole-2-carbonyl)-N-((1-methylpiperidin-4-yl)methyl)piperidine-4-carboxamide 
• 1361951-49-6 N-((1-methylpiperidin-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-5-amine 
• 1616597-89-7 2-(2-isopropylphenyl)-5-methyl-N-((1-methylpiperidin-4-yl)methyl)pyrimidin-4-amine 
• 1427588-56-4 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-N-[(1-methylpiperidin-4-yl)methyl]piperidine-2-carboxamide 
• 1427588-65-5 4-[1-(4-Chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]-N-[(1-methylpiperidin-4-yl)methyl]piperazine-1-carboxamide 
• 1417837-93-4 C₂₂H₂₅F₃N₆O₃ 
• 1417840-38-0 C₂₂H₂₅F₃N₆O₂*CH₂O₂ 
• 1417698-87-3 C₂₃H₂₆F₃N₅O₂ 

Relevant academic research and scientific papers

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

The COVID-19 pandemic has been disastrous to society and effective drugs are urgently needed. The papain-like protease domain (PLpro) of SARS-CoV-2 (SCoV2) is indispensable for viral replication and represents a putative target for pharmacological intervention. In this work, we describe the development of a potent and selective SCoV2 PLpro inhibitor, 19. The inhibitor not only effectively blocks substrate cleavage and immunosuppressive function imparted by PLpro, but also markedly mitigates SCoV2 replication in human cells, with a submicromolar IC50. We further present a convenient and sensitive activity probe, 7, and complementary assays to readily evaluate SCoV2 PLpro inhibitors in vitro or in cells. In addition, we disclose the co-crystal structure of SCoV2 PLpro in complex with a prototype inhibitor, which illuminates their detailed binding mode. Overall, these findings provide promising leads and important tools for drug discovery aiming to target SCoV2 PLpro.

PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase

To improve the antitumor properties and optimize the pharmaceutical properties including solubility and protein binding of indolin-2-ones, a number of different basic and weakly basic analogues were designed and synthesized. 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (12b or SU11248) has been found to show the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochemical and cellular levels, solubility, protein binding, and bioavailability. 12b is currently in phase I clinical trials for the treatment of cancers.

Indazole derivatives having monocyclic amine

An indazole compound having the formula (I): wherein: R1 is hydrogen, C1 -C6 alkyl, C3 -C6 alkenyl or C3 -C6 cycloalkyl; Q is carbonyl, thiocarbonyl or methylene; and R2 is a group of the formula (II) or (IV); STR1 wherein R1 is C1 -C6 alkyl, C3 -C6 alkenyl or benzyl, of which a phenyl group thereof is optionally mono- or di-substituted by the same or different halogen or methoxy; m is 0 to 2; n and o is 1 or 2. The compound exhibits 5-HT4 receptor agonist activity.

Sulfonamide compounds, compositions and method of use

Certain substituted sulfonamide quinolines and isoquinolines are disclosed having anti-allergic activity. A preferred use is for the treatment of chronic obstructive lung disease, and in particular, asthma.